

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-30 (Cancelled).

Claim 31 (Previously presented). An isolated polynucleotide comprising a first nucleic acid which encodes a polypeptide at least 80% identical a polypeptide comprising amino acids 1 to 310 of SEQ ID NO:2, wherein said polypeptide modulates inhibition of axonal elongation.

Claim 32 (Previously presented). The polynucleotide of claim 31, wherein said polypeptide is at least 90% identical to amino acids 1 to 310 of SEQ ID NO:2.

Claim 33 (Previously presented). The polynucleotide of claim 32, wherein said polypeptide is at least 95% identical to amino acids 1 to 310 of SEQ ID NO:2.

Claim 34 (Previously presented). The polynucleotide of claim 33 wherein said polypeptide comprises amino acids 1 to 310 of SEQ ID NO:2.

Claim 35 (Previously presented). The polynucleotide of claim 31, further comprising a second nucleic acid.

Claim 36 (Previously presented). The polynucleotide of claim 35, wherein said second nucleic acid encodes a heterologous polypeptide.

Claim 37 (Previously presented). The polynucleotide of claim 36, wherein said heterologous polypeptide forms a fusion protein with the polypeptide encoded by said first nucleic acid.

Claim 38 (Previously presented). The polynucleotide of claims 37, wherein said heterologous polypeptide is Fc.

Claim 39 (Previously presented). The polynucleotide of claim 37, wherein said heterologous polypeptide is selected from the group consisting of Glutathione S-transferase (GST), a Histidine tag (His tag), and alkaline phosphatase (AP).

Claim 40 (Previously presented). A vector comprising the polynucleotide of claim 31.

Claim 41 (Previously presented). The vector of claim 40, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 42 (Previously presented). A host cell comprising the polynucleotide of claim 31.

Claim 43 (Previously presented). The host cell of claim 42, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 44 (Previously presented). An isolated polynucleotide comprising a first nucleic acid which encodes a polypeptide at least 80% identical to a polypeptide comprising amino acids 31 to 310 of SEQ ID NO:2, wherein said polypeptide modulates inhibition of axonal elongation.

Claim 45 (Previously presented). The polynucleotide of claim 44, wherein said polypeptide is at least 90% identical to amino acids 31 to 310 of SEQ ID NO:2.

Claim 46 (Previously presented). The polynucleotide of claim 45, wherein said polypeptide is at least 95% identical to amino acids 31 to 310 of SEQ ID NO:2.

Claim 47 (Previously presented). The polynucleotide of claim 46, wherein said polypeptide comprises amino acids 31 to 310 of SEQ ID NO:2.

Claim 48 (Previously presented). The polynucleotide of claim 44, further comprising a second nucleic acid.

Claim 49 (Previously presented). The polynucleotide of claim 48, wherein said second nucleic acid encodes a heterologous polypeptide.

Claim 50 (Previously presented). The polynucleotide of claim 49, wherein said heterologous polypeptide forms a fusion protein with the polypeptide encoded by said first nucleic acid.

Claim 51 (Previously presented). The polynucleotide of claims 50, wherein said heterologous polypeptide is Fc.

Claim 52 (Previously presented). The polynucleotide of claim 50, wherein said heterologous polypeptide is selected from the group consisting of Glutathione S-transferase (GST), a Histidine tag (His tag), and alkaline phosphatase (AP).

Claim 53 (Previously presented). A vector comprising the polynucleotide of claim 44.

Claim 54 (Previously presented). The vector of claim 53, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 55 (Previously presented). A host cell comprising the polynucleotide of claim 44.

Claim 56 (Previously presented). The host cell of claim 55, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 57 (Previously presented). An isolated polynucleotide comprising a first nucleic acid which encodes, except for 1 to 10 conservative amino acid substitutions, a polypeptide selected from the group consisting of amino acids 1-310 of SEQ ID NO:2 and amino acids 31-310 of SEQ ID NO:2; wherein said polypeptide modulates inhibition of axonal elongation.

Claim 58 (Previously presented). The polynucleotide of claim 57, further comprising a second nucleic acid.

Claim 59 (Previously presented). The polynucleotide of claim 58, wherein said second nucleic acid encodes a heterologous polypeptide.

Claim 60 (Previously presented). The polynucleotide of claim 59, wherein said heterologous polypeptide forms a fusion protein with the polypeptide encoded by said first nucleic acid.

Claim 61 (Previously presented). The polynucleotide of claims 60, wherein said heterologous polypeptide is Fc.

Claim 62 (Previously presented). The polynucleotide of claim 60, wherein said heterologous polypeptide is selected from the group consisting of Glutathione S-transferase (GST), a Histidine tag (His tag), and alkaline phosphatase (AP).

Claim 63 (Previously presented). A vector comprising the polynucleotide of claim 57.

Claim 64 (Previously presented). The vector of claim 63, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 65 (Previously presented). A host cell comprising the polynucleotide of claim 57.

Claim 66 (Previously presented). The host cell of claim 65, wherein said polynucleotide is operably linked to one or more expression control elements.